Antibody Drug Conjugate (ADC) Market 8th Edition: Industry Trends and Global Forecasts, Till 2035

Table of Contents

SECTION I: REPORT OVERVIEW

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Question Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach

3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis

3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics

4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Pillars Of Cancer Therapy
6.3. Antibody-drug Conjugates
6.3.1. History of Antibody-Drug Conjugates
6.3.2. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody-Drug Conjugates

6.3.3. Components of Antibody-Drug Conjugates
6.3.3.1. Antibody
6.3.3.2. Cytotoxin
6.3.3.3. Linker

6.3.4. Advantages of Antibody-Drug Conjugates Over Traditional Therapeutics

6.3.5. Pharmacokinetic Properties of Antibody-Drug Conjugates
6.3.5.1. Absorption
6.3.5.2. Distribution
6.3.5.3. Metabolism and Elimination

6.4. Concluding Remarks

SECTION III: MARKET OVERVIEW

7. MARKET OVERVIEW
7.1. Chapter Overview
7.2. Antibody-Drug Conjugates: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Target Indication
7.2.3. Analysis by Therapeutics Area
7.2.4. Analysis by Line of Treatment
7.2.5. Analysis by Dosing Frequency
7.2.6. Analysis by Type of Therapy
7.2.7. Analysis by Target Antigen
7.2.8. Analysis by Antibody Isotypes
7.2.9. Analysis by Type of Linker (Cleavable / Non-cleavable)
7.2.10. Analysis by Payload / Cytotoxin / Warhead
7.2.11. Analysis by Type of Payload

7.3. Antibody-Drug Conjugate Developers: Overall Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Most Active Player: Analysis by Number of Therapies

8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Key Parameters and Scoring Criteria
8.3. Methodology

8.4. Antibody-drug Conjugates: Target Competitiveness Analysis
8.4.1. Three-Dimensional Bubble Analysis
8.4.1.1. Targets of Approved / Marketed Drugs
8.4.1.2. Targets of Phase III Drugs
8.4.1.3. Targets of Phase II Drugs
8.4.1.4. Targets of Phase I Drugs
8.4.1.5. Targets of Preclinical Stage Drugs

8.4.2. Six-Dimensional Spider Web Analysis

SECTION IV: COMPANY AND DRUG PROFILES

9. COMPANY AND DRUG PROFILES
9.1. Chapter Overview
9.2. AbbVie
9.2.1. Company Overview
9.2.2. Financial Information

9.2.3. Antibody Drug Conjugate Pipeline
9.2.3.1. Elahere
9.2.3.2. Teliso-V

9.2.4. Recent Developments and Future Outlook

9.3. ADC Therapeutics
9.3.1. Company Overview
9.3.2. Financial Information
9.3.3. Antibody Drug Conjugate Pipeline

9.3.3.1. Zynlonta

9.3.4. Recent Developments and Future Outlook

9.4. Astellas Pharma
9.4.1. Company Overview
9.4.2. Financial Information

9.4.3. Antibody Drug Conjugate Pipeline
9.4.3.1. Padcev

9.4.4. Recent Developments and Future Outlook

9.5. AstraZeneca
9.5.1. Company Overview
9.5.2. Financial Information

9.5.3. Antibody Drug Conjugate Pipeline
9.5.3.1. Enhertu

9.5.4. Recent Developments and Future Outlook

9.6. Daiichi Sankyo
9.6.1. Company Overview
9.6.2. Financial Information

9.6.3. Antibody Drug Conjugate Pipeline
9.6.3.1. Enhertu
9.6.3.2. Datroway
9.6.3.3. Patritumab Deruxtecan

9.6.4. Recent Developments and Future Outlook

9.7. Gilead Sciences
9.7.1. Company Overview
9.7.2. Financial Information

9.7.3. Antibody Drug Conjugate Pipeline
9.7.3.1. Trodelvy

9.7.4. Recent Developments and Future Outlook

9.8. GSK
9.8.1. Company Overview
9.8.2. Financial Information

9.8.3. Antibody Drug Conjugate Pipeline
9.8.3.1. Blenrep

9.8.4. Recent Developments and Future Outlook

9.9. Jiangsu Hengrui Pharmaceuticals
9.9.1. Company Overview
9.9.2. Antibody Drug Conjugate Pipeline
9.9.2.1. Trastuzumab rezetecan

9.9.3. Recent Developments and Future Outlook

9.10. Kelun-Biotech
9.10.1. Company Overview
9.10.2. Financial Information

9.10.3. Antibody Drug Conjugate Pipeline
9.10.3.1. Sacituzumab Tirumotecan
9.10.3.2. Trastuzumb Botidotin

9.10.4. Recent Developments and Future Outlook

9.11. Merck
9.11.1. Company Overview
9.11.2. Financial Information

9.11.3. Antibody Drug Conjugate Pipeline
9.11.3.1. Sacituzumab Tirumotecan
9.11.3.2. Patritumab Deruxtecan

9.11.4. Recent Developments and Future Outlook

9.12. Pfizer
9.12.1. Company Overview
9.12.2. Financial Information

9.12.3. Antibody Drug Conjugate Pipeline
9.12.3.1. Mylotarg
9.12.3.2. Besponsa
9.12.3.3. Adcetris
9.12.3.4. Padcev
9.12.3.5. Tivdak

9.12.4. Recent Developments and Future Outlook

9.13. Rakuten Medical
9.13.1. Company Overview

9.13.2. Antibody Drug Conjugate Pipeline
9.13.2.1. Akalux

9.13.3. Recent Developments and Future Outlook

9.14. RemeGen
9.14.1. Company Overview
9.14.2. Financial Information

9.14.3. Antibody Drug Conjugate Pipeline
9.14.3.1. Disitamab vedotin

9.14.4. Recent Developments and Future Outlook

9.15. Roche
9.15.1. Company Overview
9.15.2. Financial Information

9.15.3. Antibody Drug Conjugate Pipeline
9.15.3.1. Kadcyla
9.15.3.2. Polivy

9.15.4. Recent Developments and Future Outlook

SECTION V: MARKET TRENDS AND STRATEGIC FRAMEWORKS

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology

10.3. Antibody Drug Conjugates: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
10.3.3. Analysis by Trial Phase
10.3.4. Analysis of Number of Patients Enrolled by Trial Phase
10.3.5. Analysis by Trial Status
10.3.6. Analysis by Trial Registration Year and Trial Status
10.3.7. Analysis of Number of Patients Enrolled by Trial Status
10.3.8. Analysis by Patient Gender

10.3.9. Analysis by Study Design
10.3.9.1. Analysis by Type of Allocation
10.3.9.2. Analysis by Type of Intervention Model
10.3.9.3. Analysis by Type of Masking
10.3.9.4. Analysis by Trial Purpose

10.3.10. Analysis by Type of Sponsor / Collaborator
10.3.11. Leading Industry Players: Analysis by Number of Clinical Trials
10.3.12. Leading Non-Industry Players: Analysis by Number of Clinical Trials

10.3.13. Analysis by Geography
10.3.13.1. Analysis of Clinical Trials by Geography
10.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
10.3.13.3. Analysis of Patients Enrolled by Geography and Trial Status

11. KEY OPINION LEADERS
11.1. Chapter Overview
11.2. Assumption and Key Parameters
11.3. Methodology

11.4. Antibody Drug Conjugates: Key Opinion Leaders
11.4.1. Analysis by Role of KOLs
11.4.2. Analysis by Qualification
11.4.3. Analysis by Type of Organization
11.4.4. Analysis by Affiliated Organization
11.4.5. Analysis by Geographical Location of KOLs
11.4.6. Analysis by Target Disease Indication
11.4.7. Most Prominent KOLs: Analysis by KOLs Expertise, Activeness and Strength
11.4.8. Most Prominent KOLs: Analysis by RA score
11.4.9. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

12. COMBINATION THERAPIES
12.1. Chapter Overview
12.2. Combination Therapies: History and Development

12.3. Combination Therapies: FDA Guidelines
12.3.1. Combination of Marketed Drugs
12.3.2. Combinations of Marketed Drugs with New Molecular Entities
12.3.3. Combination of New Molecular Entities

12.4. Combination Therapies: Antibody Drug Conjugates
12.4.1. Completed / Ongoing Clinical Studies of Antibody Drug Conjugates
12.4.1.1. Analysis by Type of Therapy

12.4.2. Completed / Ongoing Clinical Studies of Antibody Drug Conjugate-based Combination Therapies
12.4.2.1. Analysis by Phase of Development
12.4.2.2. Analysis by Trial Status
12.4.2.3. Analysis by Target Disease Indication
12.4.2.4. Most Popular Antibody Drug Conjugates Used in Combination Therapies: Analysis by Number of Trials
12.4.2.5. Most Popular Drug Classes Used in Antibody Drug Conjugate- Based Combination Therapies: Analysis by Number of Trials

12.4.2.6. Analysis by Target Disease Indication and Drug Class Used in Antibody Drug Conjugate-Based Combination Therapies
12.4.2.6.1. Antibody Drug Conjugate-based Combination Therapies: Benchmarking of Popular Drug Classes for Blood Cancer
12.4.2.6.2. Antibody Drug Conjugate-based Combination Therapies: Benchmarking of Popular Drug Classes for Breast Cancer
12.4.2.6.3. Antibody Drug Conjugate-based Combination Therapies: Benchmarking of Popular Drug Classes for Lung Cancer
12.4.2.6.4. Antibody Drug Conjugate-based Combination Therapies: Benchmarking of Popular Drug Classes for Solid Tumor
12.4.2.6.5. Antibody Drug Conjugate-based Combination Therapies: Benchmarking of Popular Drug Classes for Gastric Cancer

13. PARTNERSHIPS AND COLLABORATIONS
13.1. Chapter Overview
13.2. Partnership Models

13.3. Antibody Drug Conjugates Market: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year and Type of Partnership

13.3.4. Analysis by Type of Partner
13.3.5. Most Active Players: Analysis by Number of Partnerships

13.3.6. Analysis by Geography
13.3.6.1. Analysis by Country
13.3.6.2. Analysis by Continent

14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Funding Models

14.3. Antibody-Drug Conjugates Market: Funding and Investment Analysis
14.3.1. Analysis by Year of Funding
14.3.1.1. Cumulative Year-wise Trend of Funding Instances
14.3.1.2. Cumulative Year-wise Trend of Amount Invested

14.3.2. Analysis by Type of Funding
14.3.2.1. Analysis of Funding Instances
14.3.2.2. Analysis of Amount Invested

14.3.3. Analysis by Year and Type of Funding
14.3.4. Analysis by Geography
14.3.5. Most Active Players: Analysis by Number of Funding Instances
14.3.6. Most Active Players: Analysis by Amount Invested

14.4. Summary of Funding and Investments

15. PATENT ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology

15.3. Antibody-Drug Conjugates: Patent Analysis
15.3.1. Analysis by Patent Publication Year
15.3.2. Analysis by Type of Patent and Publication Year
15.3.3. Analysis by Patent Application Year
15.3.4. Analysis by Patent Jurisdiction
15.3.5. Analysis by CPC Symbols
15.3.6. Analysis by Type of Applicant
15.3.7. Leading Industry Players: Analysis by Number of Patents
15.3.8. Leading Non-Industry Players: Analysis by Number of Patents

15.4. Patent Benchmarking Analysis
15.4.1. Analysis by Patent Characteristics

15.5. Patent Valuation
15.6. Leading Patents by Number of Citations

16. GRANTS ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology

16.3. Antibody Drug Conjugates: Grants Analysis
16.3.1. Analysis by Year of Grant Award
16.3.2. Analysis by Amount Awarded
16.3.3. Analysis by Funding Institute Center
16.3.4. Analysis by Support Period
16.3.5. Analysis by Type of Grant Application
16.3.6. Analysis by Purpose of Grant Award
16.3.7. Analysis by Activity Code
16.3.8. Analysis by Study Section Involved
16.3.9. Popular NIH Departments: Analysis by Number of Grants
16.3.10. Prominent Program Officers: Analysis by Number of Grants
16.3.11. Popular Recipient Organizations: Analysis by Number of Grants
16.3.12. Popular Recipient Organizations: Analysis by Grant Amount
16.3.13. Analysis by Region of Recipient Organization

17. KEY COMMERCIALIZATION STRATEGIES
17.1. Chapter Overview
17.2. Successful Drug Launch Strategy: ROOTS Framework
17.3. Successful Drug Launch Strategy: Product Differentiation
17.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development

17.5. Key Commercialization Strategies Adopted by Companies Focused on Antibody-Drug Conjugates
17.5.1. Participation in the Global Events
17.5.2. Collaboration with External Stakeholders and Pharmaceutical Firms
17.5.3. Geographical Expansion
17.5.4. Awareness Through Product Website

17.6. Concluding Remarks

18. PROMOTIONAL ANALYSIS
18.1. Chapter Overview
18.2. Channels Used for Promotional Campaigns
18.3. Summary of Product Website
18.4. Summary of Patient Support Services and Informative Downloads

18.5. Adcetris: Promotional Analysis
18.5.1. Drug Overview

18.5.2. Product Website Analysis
18.5.2.1. Message for Healthcare Professionals
18.5.2.2. Message for Patients
18.5.2.3. Informative Downloads
18.5.2.4. Patient Support Services

18.6. Besponsa: Promotional Analysis
18.6.1. Drug Overview

18.6.2. Product Website Analysis
18.6.2.1. Message for Healthcare Professionals
18.6.2.2. Message for Patients
18.6.2.3. Informative Downloads
18.6.2.4. Patient Support Services

18.7. Enhertu: Promotional Analysis
18.7.1. Drug Overview

18.7.2. Product Website Analysis
18.7.2.1. Message for Healthcare Professionals
18.7.2.2. Message for Patients
18.7.2.3. Informative Downloads
18.7.2.4. Patients Support Services

18.8. Kadcyla: Promotional Analysis
18.8.1. Drug Overview

18.8.2. Product Website Analysis
18.8.2.1. Message for Healthcare Professionals
18.8.2.2. Message for patients
18.8.2.3. Informative Downloads
18.8.2.4. Patient Support Services

18.9. Mylotarg: Promotional Analysis
18.9.1. Drug Overview

18.9.2. Product Website Analysis
18.9.2.1. Message for Healthcare Professionals
18.9.2.2. Message for patients
18.9.2.3. Informative Downloads
18.9.2.4. Patient Support Services

18.10. Polivy: Promotional Analysis
18.10.1. Drug Overview

18.10.2. Product Website Analysis
18.10.2.1. Message for Healthcare Professionals
18.10.2.2. Message for Patients
18.10.2.3. Informative Downloads
18.10.2.4. Patient Support Services

18.11. Trodelvy: Promotional Analysis
18.11.1. Drug Overview

18.11.2. Product Website Analysis
18.11.2.1. Message for Healthcare Professionals
18.11.2.2. Message for Patients
18.11.2.3. Informative Downloads
18.11.2.4. Patient Support Services

19. SUCCESS PROTOCOL ANALYSIS
19.1. Chapter Overview
19.2. Methodology and Key Parameters

19.3. Antibody Drug Conjugates: Success Protocol Analysis
19.3.1. Adcetris (Pfizer / Takeda Oncology)
19.3.1.1. Overview
19.3.1.2. Approval Timeline
19.3.1.3. Success Protocol Analysis

19.3.2. Enhertu (Daiichi Sankyo / AstraZeneca)
19.3.2.1. Overview
19.3.2.2. Approval Timeline
19.3.2.3. Success Protocol Analysis

19.3.3. Kadcyla (Genentech / ImmunoGen)
19.3.3.1. Overview
19.3.3.2. Approval Timeline
19.3.3.3. Success Protocol Analysis

19.3.4. Padcev (Pfizer / Astellas Pharma)
19.3.4.1. Overview
19.3.4.2. Approval Timeline
19.3.4.3. Success Protocol Analysis

19.3.5. Polivy (Genentech)
19.3.5.1. Overview
19.3.5.2. Approval Timeline
19.3.5.3. Success Protocol Analysis

19.3.6. Trodelvy (Gilead Sciences)
19.3.6.1. Overview
19.3.6.2. Approval Timeline
19.3.6.3. Success Protocol Analysis

19.4. Conclusion

20. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS
20.1. Chapter Overview
20.2. Antibody-Drug Conjugates: Conjugation Technologies
20.2.1. Chemical Conjugation
20.2.2. Enzymatic Conjugation

20.3. Antibody-drug Conjugates: List of Conjugation Technologies

20.4. Antibody-drug Conjugates: Linker Technologies
20.4.1. Non-cleavable Linkers
20.4.2. Cleavable Linker

20.5. Antibody-drug Conjugates: List of Linker and Linker-Payload Technologies
20.6. Concluding Remarks

21. ASSESSMENT OF ANTIBODY-DRUG CONJUGATES NON-CLINICAL DATA: FIRST ON FIRST IN HUMAN DOSING
21.1. Chapter Overview
21.2. Antibody-drug Conjugates and Non-Clinical Studies
21.3. ICH S9 Guideline

21.4. Investigational New Drug (IND)-Enabling Study Designs
21.4.1. Example Case: Kadcyla

21.5. Toxicities in Animal Models
21.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
21.7. Other Key Considerations for Study Design

22. COST PRICE ANALYSIS
22.1. Chapter Overview
22.2. Factors Contributing Towards the High Price of Antibody-Drug Conjugates

22.3. Antibody-drug Conjugates Market: Cost Price Analysis
22.3.1. On the Basis of Associated Costs
22.3.2. On the Basis of Competition
22.3.3. On the Basis of Patient Segment

22.4. Reimbursement Considerations for Antibody-Drug Conjugates

SECTION VI: CASE STUDIES

23. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES
23.1. Chapter Overview
23.2. Key Steps for Antibody-Drug Conjugate Manufacturing
23.3. Technical Challenges Related to Antibody-Drug Conjugates Manufacturing
23.4. Challenges Associated with Supply Chain and Method Transfer
23.5. Limitation of In-House Manufacturing
23.6. Investments in Antibody-Drug Conjugate Manufacturing Capability Expansions
23.7. Collaborations Established for Antibody-Drug Conjugates Manufacturing
23.8. Growing Demand for Contract Manufacturing
23.9. CMOs with Linker Manufacturing Capabilities
23.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
23.11. CMOs with Conjugation Capabilities
23.12. Antibody-Drug Conjugates One-Stop-Shops
23.13. Increasing Demand for One-Stop-Shops

24. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY-DRUG CONJUGATES
24.1. Chapter Overview
24.1.1. Advantages of Companion Diagnostics
24.1.2. Challenges Associated with the Development of Companion Diagnostics

24.2. Companion Diagnostics for Antibody-Drug Conjugates

24.3. Companion Diagnostics for Antibody Therapeutics
24.3.1. Analysis by Type of Cancer
24.3.2. Most Prominent Players: Analysis by Number of Tests

25. SWOT ANALYSIS
25.1. Chapter Overview
25.2. Strengths
25.2.1. Improved Safety and Patient Adherence
25.2.2. Rise of Next-Generation Conjugation Technologies
25.2.3. Robust Pipeline with Multiple Late-Stage Product Candidates
25.2.4. Growing Involvement of the Academic Institute

25.3. Weaknesses
25.3.1. Technical Complexities Associated with Product Development
25.3.2. Manufacturing, Logistics and Supply Chain Challenges
25.3.3. Batch to Batch Inconsistency

25.4. Opportunities
25.4.1. Increasing Collaboration and Venture Capital Funding
25.4.2. Expanding Therapeutics Reach
25.4.3. Life Cycle Management
25.4.4. Combination Therapies
25.4.5. Opportunities for CMOs

25.5. Threats
25.5.1. Failure of Clinical / Marketed Candidates
25.5.2. Increased Competition from Other Therapeutic Classes

SECTION VII: MARKET FORECAST AND OPPORTUNITY ANALYSIS

26. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET
26.1. Chapter Overview
26.2. Key Assumptions and Methodology

26.3. Global Antibody-Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3.1. Scenario Analysis
26.3.1.1. Conservative Scenario
26.3.1.2. Optimistic Scenario

26.4. Key Market Segmentations

27. ANTIBODY-DRUG CONJUGATES MARKET, BY TARGET INDICATION
27.1. Chapter Overview
27.2. Key Assumptions and Methodology

27.3. Antibody-Drug Conjugates Market: Distribution by Target Indication
27.3.1. Antibody-Drug Conjugates Market for Breast Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.2. Antibody-Drug Conjugates Market for Lung Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.3. Antibody-Drug Conjugates Market For B-cell Lymphoma: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.4. Antibody-Drug Conjugates Market for Multiple Myeloma: Forecasted Estimates (Till 2035)
27.3.5. Antibody-Drug Conjugates Market for Ovarian Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.6. Antibody-Drug Conjugates Market for Renal Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.7. Antibody-Drug Conjugates Market for Gastric Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.8. Antibody-Drug Conjugates Market for Hodgkin's Lymphoma: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
27.3.9. Antibody-Drug Conjugates Market for Other Target Indications: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.4. Data Triangulation and Validation

28. ANTIBODY-DRUG CONJUGATES MARKET, BY THERAPEUTICS AREA
28.1. Chapter Overview
28.2. Key Assumptions and Methodology

28.3. Antibody-Drug Conjugates Market: Distribution by Therapeutic Area
28.3.1. Antibody-Drug Conjugates Market for Solid Tumors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
28.3.2. Antibody-Drug Conjugates Market for Hematological Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.4. Data Triangulation and Validation

29. ANTIBODY-DRUG CONJUGATES MARKET, BY LINKER
29.1. Chapter Overview
29.2. Key Assumptions and Methodology

29.3. Antibody-Drug Conjugates Market: Distribution by Linker
29.3.1. Antibody-Drug Conjugates Market for Tetrapeptide-based Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.2. Antibody-Drug Conjugates Market for Valine-citrulline Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.3. Antibody-Drug Conjugates Market for SMCC Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.4. Antibody-Drug Conjugates Market for Maleimidocaproyl Linker: Forecasted Estimates (Till 2035)
29.3.5. Antibody-Drug Conjugates Market for Maleimide Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.6. Antibody-Drug Conjugates Market for Sulfo-SPDB Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
29.3.7. Antibody-Drug Conjugates Market for Tetrapeptide- maleimide-linker: Forecasted Estimates (Till 2035)
29.3.8. Antibody-Drug Conjugates Market for GGFG (peptide) Linker: Forecasted Estimates (Till 2035)
29.3.9. Antibody-Drug Conjugates Market for Other Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.4. Data Triangulation and Validation

30. ANTIBODY-DRUG CONJUGATES MARKET, BY PAYLOAD
30.1. Chapter Overview
30.2. Key Assumptions and Methodology

30.3. Antibody-Drug Conjugates Market: Distribution by Payload
30.3.1. Antibody-Drug Conjugates Market for Monomethyl auristatin E (MMAE) Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.2. Antibody-Drug Conjugates Market for Camptothecin: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.3. Antibody-Drug Conjugates Market for Exatecan: Forecasted Estimates (Till 2035)
30.3.4. Antibody-Drug Conjugates Market for DM1: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.5. Antibody-Drug Conjugates Market for Monomethyl auristatin F (MMAF): Forecasted Estimates (Till 2035)
30.3.6. Antibody-Drug Conjugates Market for SN-38 / Irinotecan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.7. Antibody-Drug Conjugates Market for DM4: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
30.3.8. Antibody-Drug Conjugates Market for Other Payloads: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

30.4. Data Triangulation and Validation

31. ANTIBODY-DRUG CONJUGATES MARKET, BY TARGET ANTIGEN
31.1. Chapter Overview
31.2. Key Assumptions and Methodology

31.3. Antibody-Drug Conjugates Market: Distribution by Target Antigen
31.3.1. Antibody-Drug Conjugates Market for HER-2 (ERBB2): Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
31.3.2. Antibody-Drug Conjugates Market for TROP-2: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
31.3.3. Antibody-Drug Conjugates Market for CD79b: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
31.3.4. Antibody-Drug Conjugates Market for BCMA (TNFRSF17 / BCM): Forecasted Estimates (Till 2035)
31.3.5. Antibody-Drug Conjugates Market for FOLR1 (Folate receptor alpha): Forecasted Estimates (Till 2035)
31.3.6. Antibody-Drug Conjugates Market for c-MET: Forecasted Estimates (Till 2035)
31.3.7. Antibody-Drug Conjugates Market for Nectin-4: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
31.3.8. Antibody-Drug Conjugates Market for CD30: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
31.3.9. Antibody-Drug Conjugates Market for Integrin beta-6: Forecasted Estimates (Till 2035)
31.3.10. Antibody-Drug Conjugates Market for Other Antigens: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

31.4. Data Triangulation and Validation

32. ANTIBODY-DRUG CONJUGATES MARKET, BY GEOGRAPHICAL REGIONS
32.1. Chapter Overview
32.2. Key Assumptions and Methodology

32.3. Antibody-Drug Conjugates Market: Distribution by Geographical Regions
32.3.1. Antibody-Drug Conjugates Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.1.1. Antibody-Drug Conjugates Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.1.2. Antibody-Drug Conjugates Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

32.3.2. Antibody-Drug Conjugates Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.2.1. Antibody-Drug Conjugates Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.2.2. Antibody-Drug Conjugates Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.2.3. Antibody-Drug Conjugates Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.2.4. Antibody-Drug Conjugates Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.2.5. Antibody-Drug Conjugates Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

32.3.3. Antibody-Drug Conjugates Market in Asia-Pacific and Rest of the World: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.3.1. Antibody-Drug Conjugates Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.3.2. Antibody-Drug Conjugates Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
32.3.3.3. Antibody-Drug Conjugates Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

32.4. Penetration Growth (P-G) Matrix
32.5. Data Triangulation and Validation

33. ANTIBODY-DRUG CONJUGATES MARKET, SALES FORECAST OF THERAPIES
33.1. Chapter Overview
33.2. Key Assumptions and Methodology

33.3. Commercialized Antibody-Drug Conjugate Therapies: Sales Forecast
33.3.1. Enhertu (Trastuzumab Deruxtecan) Sales Forecast
33.3.2. Polivy (Polatuzumab Vedotin) Sales Forecast
33.3.3. Kadcyla (Trastuzumab Emtansine) Sales Forecast
33.3.4. Trodelvy (Sacituzumab Govitecan) Sales Forecast
33.3.5. Elahere (Mirvetuximab Soravtansine) Sales Forecast
33.3.6. Padcev (Enfortumab Vedotin-ejfv) Sales Forecast
33.3.7. Adcetris (Brentuximab Vedotin) Sales Forecast
33.3.8. Aidixi (Disitamab Vedotin) Sales Forecast
33.3.9. Tivdak (Tisotumab Vedotin) Sales Forecast
33.3.10. Besponsa (Inotuzumab Ozogamicin) Sales Forecast
33.3.11. Sacituzumab Tirumotecan (SKB264) Sales Forecast
33.3.12. Zynlonta (Loncastuximab Tesirine) Sales Forecast

33.4. BLA-Summited and Phase III Antibody-Drug Conjugate Therapies: Sales Forecast
33.4.1. Datroway (Datopotamab Deruxtecan) Sales Forecast
33.4.2. Blenrep (Belantamab Mafodotin) Sales Forecast
33.4.3. Telisotuzumab Vedotin (Teliso-V / ABBV-399) Sales Forecast
33.4.4. Sigvotatug Vedotin (PF08046047 / SGN-B6A) Sales Forecast
33.4.5. Trastuzumab Rezetecan (SHR-A1811) Sales Forecast
33.4.6. DB-1303 (BNT-323) Sales Forecast
33.4.7. Telisotuzumab Adizutecan (Temab-A / ABBV-400) Sales Forecast
33.4.8. JSKN003 Sales Forecast
33.4.9. Patritumab Deruxtecan (U3-1402 / MK-1020) Sales Forecast
33.4.10. Ifinatamab Deruxtecan (MK-2400 / DS-7300) Sales Forecast
33.4.11. GSK5764227 (HS-20093) Sales Forecast

SECTION VIII: OTHER EXCLUSIVE INSIGHTS

34. CONCLUSION REMARKS

35. INSIGHTS FROM PRIMARY RESEARCH

35.1. Chapter Overview
35.2. Company A
35.2.1. Company Snapshot
35.2.2. Interview Transcript: Founder and Chief Executive Officer

35.3. Company B
35.3.1. Company Snapshot
35.3.2. Interview Transcript: Founder and Chief Operating Officer

35.4. Company c
35.4.1. Company Snapshot
35.4.2. Interview Transcript: Co-Founder and Chief Executive Officer

35.5. Company D
35.5.1. Company Snapshot
35.5.2. Interview Transcript: President and Chief Executive Officer and Technical Business Development Senior Manager

35.6. Company E
35.6.1. Company Snapshot
35.6.2. Interview Transcript: Former Chief Executive Officer

35.7. Company F
35.7.1. Company Snapshot
35.7.2. Interview Transcript: Founder and Chief Executive Officer

35.8. Company G
35.8.1. Company Snapshot
35.8.2. Interview Transcript: Chief Business Officer and Head of Strategy

35.9. Company H
35.9.1. Company Snapshot
35.9.2. Interview Transcript: Former Chief Business Officer

35.10. Company I
35.10.1. Company Snapshot
35.10.2. Interview Transcript: Chief Commercial Officer

35.11. Company J
35.11.1. Company Snapshot
35.11.2. Interview Transcript: President, and Senior Vice President and Chief Scientific Officer

35.12. Company K
35.12.1. Company Snapshot
35.12.2. Interview Transcript: Chief Business Officer

35.13. Company L
35.13.1. Company Snapshot
35.13.2. Interview Transcript: Former Vice President and Head of Chemistry

35.14. Company M
35.14.1. Company Snapshot
35.14.2. Interview Transcript: Vice President, Business Development

35.15. Company N
35.15.1. Company Snapshot
35.15.2. Interview Transcript: Former Director

35.16. Company O
35.16.1. Company Snapshot
35.16.2. Interview Transcript: Former Director, SMARTag ADCs and Bioconjugates and Former Group Product Manager

35.17. Company P
35.17.1. Company Snapshot
35.17.2. Interview Transcript: Former Head of Bioconjugates Commercial Development

35.18. Company Q
35.18.1. Company Snapshot
35.18.2. Interview Transcript: Former Site Head

35.19. Company R
35.19.1. Company Snapshot
35.19.2. Interview Transcript: General Manager, Business Development, CDMO Business

35.20. Company S
35.20.1. Company Snapshot
35.20.2. Interview Transcript: Professor, School of Medicine

35.21. Anonymous Director, Business Development, Leading CMO
35.22. Anonymous Chief Executive Officer, Leading CMO

SECTION IX: APPENDICES

36. APPENDIX I: TABULATED DATA

37. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Antibody-Drug Conjugates Market Landscape
Figure 5.2 Executive Summary: Market Trends Analysis
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Pillars of Cancer Therapy
Figure 6.2 Development History of Antibody-Drug Conjugates
Figure 6.3 Comparative Analysis of Pharmacokinetic Properties of Antibody-drug Conjugates: Dosage Regimen, Cmax and T1/2
Figure 6.4 Components of Antibody-drug Conjugates
Figure 7.1 Antibody-Drug Conjugates: Distribution by Stage of Development
Figure 7.2 Antibody-Drug Conjugates: Distribution by Target Indication
Figure 7.3 Antibody-Drug Conjugates: Distribution by Therapeutic Area
Figure 7.4 Antibody-Drug Conjugates: Distribution by Line of Treatment
Figure 7.5 Antibody-Drug Conjugates: Distribution by Dosing Frequency
Figure 7.6 Antibody-Drug Conjugates: Distribution by Type of Therapy
Figure 7.7 Antibody-Drug Conjugates: Distribution by Target Antigen
Figure 7.8 Antibody-Drug Conjugates: Distribution by Antibody Isotypes
Figure 7.9 Antibody-Drug Conjugates: Distribution by Type of Linker (Cleavable/Non-Cleavable)
Figure 7.10 Antibody-Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Figure 7.11 Antibody-Drug Conjugates: Distribution by Type of Payload
Figure 7.12 Antibody-Drug Conjugate Developers: Distribution by Year of Establishment
Figure 7.13 Antibody-Drug Conjugate Developers: Distribution by Company Size
Figure 7.14 Antibody-Drug Conjugate Developers: Distribution by Location of Headquarters (Region)
Figure 7.15 Antibody-Drug Conjugate Developers: Distribution by Location of Headquarters (Country)
Figure 7.16 Most Active Players: Distribution by Number of Antibody-Drug Conjugates
Figure 8.1 Antibody Drug Conjugates: 3D Bubble Analysis for Targets of Approved / Marketed Drugs
Figure 8.2 Antibody Drug Conjugates: 3D Bubble Analysis for Targets of Phase III Drugs
Figure 8.3 Antibody Drug Conjugates: 3D Bubble Analysis for Targets of Phase II Drugs
Figure 8.4 Antibody Drug Conjugates: 3D Bubble Analysis for Targets of Phase I Drugs
Figure 8.5 Antibody Drug Conjugates: 3D Bubble Analysis for Targets of Preclinical Stage Targets
Figure 8.6 Antibody Drug Conjugates: Six-Dimensional Spider Web Analysis
Figure 9.1 AbbVie: Annual Revenues, FY 2021-FY 2024 (USD Billion
Figure 9.2 ADC Therapeutics: Annual Revenues, FY 2021 - 9M FY 2024 (USD Million)
Figure 9.3 Astellas Pharma: Annual Revenues, FY 2021 -9M FY 2024 (YEN Billion)
Figure 9.4 AstraZeneca: Annual Revenues, FY 2021- FY 2024 (USD Billion)
Figure 9.5 Daiichi Sankyo: Annual Revenues, FY 2021 – 9M FY 2024 (JPY Billion)
Figure 9.6 Gilead Sciences: Annual Revenues, FY 2021-FY 2024 (USD Billion)
Figure 9.7 GSK: Annual Revenues, FY 2021-FY 2024 (GBP Billion)
Figure 9.8 GSK: Annual Revenues, FY 2021-FY 2024 (GBP Billion)
Figure 9.9 Merck: Annual Revenues, FY 2021-FY 2024 (USD Billion)
Figure 9.10 Pfizer: Annual Revenues, FY 2021 - FY 2024 (USD Billion)
Figure 9.11 RemeGen: Annual Revenues, FY 2021-FY 2024 (RMB Million)
Figure 9.12 Roche: Annual Revenues, FY 2021 –FY 2024 (CHF Billion)
Figure 10.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2021-2024
Figure 10.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2021-2024
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2021–2024
Figure 10.7 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Status
Figure 10.8 Clinical Trial Analysis: Distribution by Patient Gender
Figure 10.9 Clinical Trial Analysis: Distribution by Type of Allocation
Figure 10.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 10.11 Clinical Trial Analysis: Distribution by Type of Masking
Figure 10.12 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 10.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.14 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 10.15 Leading Non-Industry Players: Distribution by Number of Clinical Trials
Figure 10.16 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 10.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 10.18 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 11.1 KOL Analysis: Distribution by Role of KOLs
Figure 11.2 KOL Analysis: Distribution by Qualification
Figure 11.3 KOL Analysis: Distribution by Type of Organization
Figure 11.4 KOL Analysis: Distribution by Affiliated Organization
Figure 11.5 KOL Analysis: Distribution by Location of Clinical Trials
Figure 11.6 KOL Analysis: Distribution by Target Disease Indications
Figure 11.7 Most Prominent KOLs: Distribution by Activeness, Expertise and Strength of KOL
Figure 11.8 Most Prominent KOLs: Distribution by Roots Analysis Score
Figure 11.9 Most Prominent KOLs: Comparison of RA Score and Third-Party Score
Figure 12.1 Antibody Drug Conjugates Clinical Studies: Distribution by Trial Registration Year and Type of Therapy
Figure 12.2 Antibody Drug Conjugate-based Combination Therapies: Distribution by Phase of Development
Figure 12.3 Antibody Drug Conjugate-based Combination Therapies: Distribution by Trial Status
Figure 12.4 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication
Figure 12.5 Most Popular Antibody Drug Conjugates Used in Combination Therapies: Distribution by Number of Trials
Figure 12.6 Most Popular Drug Classes Used in Antibody Drug Conjugate-based Combination Therapies: Distribution by Number of Trials
Figure 12.7 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication and Type of Drug Class
Figure 12.8 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Blood Cancer
Figure 12.9 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Breast Cancer
Figure 12.10 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Lung Cancer
Figure 12.11 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Solid Tumor
Figure 12.12 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Gastric Cancer
Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2020-2025
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2020-2025
Figure 13.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 13.5 Most Active Players: Distribution by Number of Partnerships
Figure 13.6 Partnerships and Collaborations: Distribution by Country
Figure 13.7 Partnerships and Collaborations: Distribution by Continent
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, 2020-2025
Figure 14.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, 2020-2025 (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 14.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 14.5 Funding and Investment Analysis: Distribution by Year and Type of Funding, 2020-2025
Figure 14.6 Funding and Investments: Distribution of Funding Instances by Geography
Figure 14.7 Most Active Players: Distribution by Number of Funding Instances
Figure 14.8 Most Active Players: Distribution by Amount Invested
Figure 14.9 Summary of Funding and Investments
Figure 15.1 Patent Analysis: Distribution by Type of Patent
Figure 15.2 Patent Analysis: Distribution by Patent Publication Year, 2020-2025
Figure 15.3 Patent Analysis: Distribution by Type of Patent and Publication Year, 2020-2025
Figure 15.4 Patent Analysis: Distribution by Patent Application Year, Pre-2019-2024
Figure 15.5 Patent Analysis: Patent Jurisdiction
Figure 15.6 Patent Analysis: Distribution by CPC Symbols
Figure 15.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2020-2025
Figure 15.8 Leading Industry Players: Distribution by Number of Patents
Figure 15.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 15.10 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 15.11 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 15.12 Patent Analysis: Distribution by Patent Age
Figure 15.13 Antibody-Drug Conjugates: Patent Valuation
Figure 16.1 Grants Analysis: Cumulative Distribution by Year of Grant, 2020-2025
Figure 16.2 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2020-2025
Figure 16.3 Grants Analysis: Distribution by Funding Institute Center
Figure 16.4 Grants Analysis: Distribution by Support Period
Figure 16.5 Grants Analysis: Distribution by Type of Grant Application
Figure 16.6 Grants Analysis: Distribution by Purpose of Grant Award
Figure 16.7 Grants Analysis: Distribution by Activity Code
Figure 16.8 Grants Analysis: Distribution by Study Section Involved
Figure 16.9 Popular NIH Departments: Distribution by Number of Grants
Figure 16.10 Popular Recipient Organizations: Distribution by Number of Grants
Figure 16.11 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 16.12 Grants Analysis: Distribution by Region of Recipient Organization
Figure 17.1 Successful Drug Launch Strategy: ROOTS Framework
Figure 17.2 Successful Drug Launch Strategy: Product Differentiation
Figure 17.3 Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 17.4 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Developing Antibody-drug Conjugates
Figure 17.5 Antibody-drug Conjugates Approval in Multiple Geographies: Historical Timeline
Figure 17.6 Approved Antibody-drug Conjugates: Snapshot of Promotional Activities on Product Website
Figure 18.1 Channels Used for Promotional Campaigns
Figure 18.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 18.3 Product Website Analysis: Adcetris, Messages for Healthcare Professionals
Figure 18.4 Product Website Analysis: Adcetris, Messages for Patients
Figure 18.5 Product Website Analysis: Adcetris, Patient Support Program
Figure 18.6 Product Website Analysis: Besponsa, Messages for Healthcare Professionals
Figure 18.7 Product Website Analysis: Besponsa, Messages for Patients
Figure 18.8 Product Website Analysis: Besponsa, Patient Support Program
Figure 18.9 Product Website Analysis: Enhertu, Messages for Healthcare Professionals
Figure 18.10 Product Website Analysis: Enhertu, Messages for Patients
Figure 18.11 Product Website Analysis: Enhertu, Patient Support Program
Figure 18.12 Product Website Analysis: Kadcyla, Messages for Healthcare Professionals
Figure 18.13 Product Website Analysis: Kadcyla, Messages for Patients
Figure 18.14 Product Website Analysis: Mylotarg, Messages for Healthcare Professionals
Figure 18.15 Product Website Analysis: Messages for Patients
Figure 18.16 Product Website Analysis: Patient Support Program
Figure 18.17 Product Website Analysis: Pfizer Oncology Together Program
Figure 18.18 Product Website Analysis: Polivy, Messages for Healthcare Professionals
Figure 18.19 Product Website Analysis: Polivy, Messages for Patients
Figure 18.20 Product Website Analysis: Polivy, Patient Support Program
Figure 18.21 Product Website Analysis: Trodelvy, Messages for Healthcare Professionals
Figure 18.22 Product Website Analysis: Messages for Patients
Figure 18.23 Product Website Analysis: Trodelvy, Patient Support Program
Figure 19.1 Adcetris (Pfizer / Takeda Oncology): Approval Timeline
Figure 19.2 Adcetris (Pfizer / Takeda Oncology): Success Protocol Analysis
Figure 19.3 Enhertu (Daiichi Sankyo / AstraZeneca): Approval Timeline
Figure 19.4 Enhertu (Pfizer / Takeda Oncology): Success Protocol Analysis
Figure 19.5 Kadcyla (Genentech / ImmunoGen): Approval Timeline
Figure 19.6 Kadcyla (Genentech / ImmunoGen): Success Protocol Analysis
Figure 19.7 Padcev (Pfizer / Astellas Pharma): Approval Timeline
Figure 19.8 Padcev (Pfizer / Astellas Pharma): Success Protocol Analysis
Figure 19.9 Polivy (Genentech): Approval Timeline
Figure 19.10 Polivy (Genentech): Success Protocol Analysis
Figure 19.11 Trodelvy (Gilead Sciences): Approval Timeline
Figure 19.12 Trodelvy (Gilead Sciences): Success Protocol Analysis
Figure 19.13 Success Protocol Analysis: Leading Parameters
Figure 20.1 Types of Linkers
Figure 21.1 First in Human Dose Calculation: Dose Escalation using BSA Conversion
Figure 21.2 Maximum Tolerated Dose (MTD): Relationship between Drug to Antibody Ratio and Highest Non-Severely Toxic Dose (HNSTD)
Figure 22.1 Antibody-drug Conjugates: Key Manufacturing Steps
Figure 22.2 Antibody-drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing
Figure 22.3 Antibody-drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing (With Licensing Fees)
Figure 22.4 Antibody-drug Conjugates: Pricing Model Based on Patient Segment
Figure 23.1 Antibody-drug Conjugates: Manufacturing Steps
Figure 23.2 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Scale of Operation
Figure 23.3 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Figure 24.1 Advantages of Companion Diagnostics
Figure 24.2 Failure Rates: Distribution by Type of Drug Class
Figure 24.3 Companion Diagnostics: Primary Development Challenges
Figure 24.4 Companion Diagnostics for Antibody Therapeutics: Distribution by Type of Cancer
Figure 24.5 Companion Diagnostics Applicable to Antibody-drug Conjugates: Distribution by Key Players
Figure 25.1 Antibody-drug Conjugates: SWOT Analysis
Figure 25.2 Antibody-drug Conjugates SWOT Analysis: Strengths
Figure 25.3 Antibody-drug Conjugates SWOT Analysis: Weaknesses
Figure 25.4 Antibody-drug Conjugates SWOT Analysis: Opportunities
Figure 25.5 Antibody-drug Conjugates SWOT Analysis: Threats
Figure 26.1 Global Antibody-Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.2 Global Antibody-Drug Conjugates Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
Figure 26.3 Global Antibody-Drug Conjugates Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
Figure 27.1 Antibody-Drug Conjugates Market: Distribution by Target Indication (USD Billion)
Figure 27.2 Antibody-Drug Conjugates Market for Breast Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.3 Antibody-Drug Conjugates Market for Lung Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.4 Antibody-Drug Conjugates Market for B-cell Lymphoma: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.5 Antibody-Drug Conjugates Market for Multiple Myeloma: Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.6 Antibody-Drug Conjugates Market for Ovarian Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.7 Antibody-Drug Conjugates Market for Renal Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.8 Antibody-Drug Conjugates Market for Gastric Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.9 Antibody-Drug Conjugates Market for Hodgkin’s Lymphoma: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.10 Antibody-Drug Conjugates Market for Other Target Indications: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.1 Antibody-Drug Conjugates Market: Distribution by Therapeutic Area (USD Billion)
Figure 28.2 Antibody-Drug Conjugates Market for Solid Tumor: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.3 Antibody-Drug Conjugates Market for Hematological Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.1 Antibody-Drug Conjugates Market: Distribution by Linker (USD Billion)
Figure 29.2 Antibody-Drug Conjugates Market for Tetrapeptide-based Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.3 Antibody-Drug Conjugates Market for Valine-citrulline Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.4 Antibody-Drug Conjugates Market for SMCC Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.5 Antibody-Drug Conjugates Market for Maleimidocaproyl Linker: Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.6 Antibody-Drug Conjugates Market for Maleimide Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.7 Antibody-Drug Conjugates Market for Sulfo-SPDB Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.8 Antibody-Drug Conjugates Market for Tetrapeptide-Maleimide-Linker: Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.9 Antibody-Drug Conjugates Market for GGFG (Peptide) Linker: Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.10 Antibody-Drug Conjugates Market for Other Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.1 Antibody-Drug Conjugates Market: Distribution by Payload (USD Billion)
Figure 30.2 Antibody-Drug Conjugates Market for Monomethyl Auristatin E (MMAE) Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.3 Antibody-Drug Conjugates Market for Camptothecin Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.4 Antibody-Drug Conjugates Market for Exatecan Payload: Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.5 Antibody-Drug Conjugates Market for DM1 Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.6 Antibody-Drug Conjugates Market for Monomethyl Auristatin F (MMAF) Payload: Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.7 Antibody-Drug Conjugates Market for SN-38 / Irinotecan Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.8 Antibody-Drug Conjugates Market for DM4 Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.9 Antibody-Drug Conjugates Market for Other Payloads: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.1 Antibody-Drug Conjugates Market: Distribution by Target Antigen (USD Billion)
Figure 31.2 Antibody-Drug Conjugates Market for HER-2 (ERBB2): Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.3 Antibody-Drug Conjugates Market for TROP-2: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.4 Antibody-Drug Conjugates Market for CD79b: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.5 Antibody-Drug Conjugates Market for BCMA (TNFRSF17 / BCM): Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.6 Antibody-Drug Conjugates Market for FOLR1 (Folate Receptor Alpha): Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.7 Antibody-Drug Conjugates Market for c-MET: Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.8 Antibody-Drug Conjugates Market for Nectin-4: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.9 Antibody-Drug Conjugates Market for CD30: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.10 Antibody-Drug Conjugates Market for Integrin Beta-6: Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.11 Antibody-Drug Conjugates Market for Other Antigens: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.1 Antibody-Drug Conjugates Market: Distribution by Geographical Regions (USD Billion)
Figure 32.2 Antibody-Drug Conjugates Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.3 Antibody-Drug Conjugates Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.4 Antibody-Drug Conjugates Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.5 Antibody-Drug Conjugates Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.6 Antibody-Drug Conjugates Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.7 Antibody-Drug Conjugates Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.8 Antibody-Drug Conjugates Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.9 Antibody-Drug Conjugates Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.10 Antibody-Drug Conjugates Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.11 Antibody-Drug Conjugates Market in Asia-Pacific and Rest of the World: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.12 Antibody-Drug Conjugates Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.13 Antibody-Drug Conjugates Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.14 Antibody-Drug Conjugates Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 32.15 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 33.1 Antibody-Drug Conjugates Market: Enhertu (Trastuzumab Deruxtecan) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.2 Antibody-Drug Conjugates Market: Polivy (Polatuzumab Vedotin) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.3 Antibody-Drug Conjugates Market: Kadcyla (Trastuzumab Emtansine) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.4 Antibody-Drug Conjugates Market: Trodelvy (Sacituzumab Govitecan) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.5 Antibody-Drug Conjugates Market: Elahere (Mirvetuximab Soravtansine) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.6 Antibody-Drug Conjugates Market: Padcev (Enfortumab Vedotin-ejfv) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.7 Antibody-Drug Conjugates Market: Adcetris (Brentuximab Vedotin) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.8 Antibody-Drug Conjugates Market: Aidixi (Disitamab Vedotin) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.9 Antibody-Drug Conjugates Market: Tivdak (Tisotumab Vedotin) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.10 Antibody-Drug Conjugates Market: Besponsa (Inotuzumab Ozogamicin) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.11 Antibody-Drug Conjugates Market: Sacituzumab Tirumotecan (SKB264) Sales Forecast, Till 2035 (USD Billion)
Figure 33.12 Antibody-Drug Conjugates Market: Zynlonta (Loncastuximab Tesirine) Sales Forecast, 2023-2035 (USD Billion)
Figure 33.13 Antibody-Drug Conjugates Market: Datroway (Datopotamab Deruxtecan) Sales Forecast, Till 2035 (USD Billion)
Figure 33.14 Antibody-Drug Conjugates Market: Blenrep (Belantamab Mafodotin) Sales Forecast, Till 2035 (USD Billion)
Figure 33.15 Antibody-Drug Conjugates Market: Telisotuzumab Vedotin (Teliso-V / ABBV-399) Sales Forecast, Till 2035 (USD Billion
Figure 33.16 Antibody-Drug Conjugates Market: Sigvotatug Vedotin (PF08046047 / SGN-B6A) Sales Forecast, 2030-2035 (USD Billion)
Figure 33.17 Antibody-Drug Conjugates Market: Trastuzumab Rezetecan (SHR-A1811) Sales Forecast, 2028-2035 (USD Billion)
Figure 33.18 Antibody-Drug Conjugates Market: DB-1303 (BNT-323) Sales Forecast, 2030-2035 (USD Billion)
Figure 33.19 Antibody-Drug Conjugates Market: Telisotuzumab Adizutecan (Temab-A / ABBV-400) Sales Forecast, 2031-2035 (USD Billion)
Figure 33.20 Antibody-Drug Conjugates Market: JSKN003 Sales Forecast, Till 2035 (USD Billion)
Figure 33.21 Antibody-Drug Conjugates Market: Patritumab Deruxtecan (U3-1402 / MK-1020) Sales Forecast, Till 2035 (USD Billion)
Figure 33.22 Antibody-Drug Conjugates Market: Ifinatamab Deruxtecan (MK-2400 / DS-7300) Sales Forecast, 2029-2035 (USD Billion)
Figure 33.23 Antibody-Drug Conjugates Market: GSK5764227 (HS-20093) Sales Forecast, Till 2035 (USD Billion)
Figure 34.1 Concluding Remarks: Antibody-Drug Conjugates Market Landscape
Figure 34.2 Concluding Remarks: Antibody-Drug Conjugates Clinical Trial Analysis
Figure 34.3 Concluding Remarks: Partnerships and Collaborations
Figure 34.4 Concluding Remarks: Funding and Investments Analysis
Figure 34.5 Concluding Remarks: Patent Analysis
Figure 34.6 Concluding Remarks: Grants Analysis
Figure 34.7 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 34.8 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)

List of Tables

Table 6.1 Characteristics of Small Molecules and Monoclonal Antibodies and Antibody-drug Conjugates
Table 6.2 Commonly Used Cytotoxins for Antibody-drug Conjugates
Table 6.3 Characteristics of First, Second and Third Generation Antibody-drug Conjugates
Table 7.1 Antibody-Drug Conjugates: Information on Developer, Stage of Development, Target Indication and Therapeutic Area
Table 7.2 Antibody-Drug Conjugates: Information on Drug Candidates, Line of Treatment, Dosing Frequency and Type of Therapy
Table 7.3 Antibody-Drug Conjugates: Information on Target Antigen, Antibody Isotype, Type of Linker (Cleavable and Non-Cleavable), Payload / Cytotoxin / Warhead Type of Payload
Table 7.4 Antibody-Drug Conjugate Developers: Information on Year of Establishment, Location of Headquarters (Country / Region), and Company Size
Table 8.1 Target Competitiveness Analysis: Information on Novel Preclinical Stage Targets, ADC, Developer and Target Indication
Table 9.1 Antibody Drug Conjugate Developers: List of Companies Profiled
Table 9.2 AbbVie: Company Overview
Table 9.3 AbbVie: Antibody Drug Conjugate Pipeline
Table 9.4 Drug Profile: Elahere
Table 9.5 Drug Profile: Teliso-V
Table 9.6 AbbVie: Recent Developments and Future Outlook
Table 9.7 ADC Therapeutics: Company Overview
Table 9.8 ADC Therapeutics: Antibody Drug Conjugate Pipeline
Table 9.9 Drug Profile: Zynlonta
Table 9.10 ADC Therapeutics: Recent Developments and Future Outlook
Table 9.11 Astellas Pharma: Company Overview
Table 9.12 Astellas Pharma: Antibody Drug Conjugate Pipeline
Table 9.13 Drug Profile: Padcev
Table 9.14 Astellas Pharma: Recent Developments and Future Outlook
Table 9.15 AstraZeneca: Company Overview
Table 9.16 AstraZeneca: Antibody Drug Conjugate Pipeline
Table 9.17 Drug Profile: Enhertu
Table 9.18 AstraZeneca: Recent Developments and Future Outlook
Table 9.19 Daiichi Sankyo: Company Overview
Table 9.20 Daiichi Sankyo: Antibody Drug Conjugate Pipeline
Table 9.21 Drug Profile: Enhertu
Table 9.22 Drug Profile: Datroway
Table 9.23 Drug Profile: Patritumab Deruxtecan
Table 9.24 Daiichi Sankyo: Recent Developments and Future Outlook
Table 9.25 Gilead Sciences: Company Overview
Table 9.26 Gilead Sciences: Antibody Drug Conjugate Pipeline
Table 9.27 Drug Profile: Trodelvy
Table 9.28 Gilead Sciences: Recent Developments and Future Outlook
Table 9.29 GSK: Company Overview
Table 9.30 GSK: Antibody Drug Conjugate Pipeline
Table 9.31 Drug Profile: Blenrep
Table 9.32 GSK: Recent Developments and Future Outlook
Table 9.33 Jiangsu Hengrui Pharmaceuticals: Company Overview
Table 9.34 Jiangsu Hengrui Pharmaceuticals: Antibody Drug Conjugate Pipeline
Table 9.35 Drug Profile: Trastuzumab Rezetecan
Table 9.36 Jiangsu Hengrui Pharmaceuticals: Recent Developments and Future Outlook
Table 9.37 Kelun-Biotech: Company Overview
Table 9.38 Kelun-Biotech: Antibody Drug Conjugate Pipeline
Table 9.39 Drug Profile: Sacituzumab Tirumotecan
Table 9.40 Drug Profile: Trastuzumb Botidotin
Table 9.41 Kelun-Biotech: Recent Developments and Future Outlook
Table 9.42 Merck: Company Overview
Table 9.43 Merck: Antibody Drug Conjugate Pipeline
Table 9.44 Drug Profile: Sacituzumab Tirumotecan
Table 9.45 Drug Profile: Patritumab Deruxtecan
Table 9.46 Merck: Recent Developments and Future Outlook
Table 9.47 Pfizer: Company Overview
Table 9.48 Pfizer: Antibody Drug Conjugate Pipeline
Table 9.49 Drug Profile: Mylotarg
Table 9.50 Drug Profile: Besponsa
Table 9.51 Drug Profile: Adcetris
Table 9.52 Drug Profile: Padcev
Table 9.53 Drug Profile: Tivdak
Table 9.54 Pfizer: Recent Developments and Future Outlook
Table 9.55 Rakuten Medical: Company Overview
Table 9.56 Rakuten Medical: Antibody Drug Conjugate Pipeline
Table 9.57 Drug Profile: Akalux
Table 9.58 Rakuten Medical: Recent Developments and Future Outlook
Table 9.59 Rakuten Medical: Recent Developments and Future Outlook
Table 9.60 RemeGen: Antibody Drug Conjugate Pipeline
Table 9.61 Drug Profile: Disitamab Vedotin
Table 9.62 RemeGen: Recent Developments and Future Outlook
Table 9.63 Roche: Company Overview
Table 9.64 Roche: Antibody Drug Conjugate Pipeline
Table 9.65 Drug Profile: Kadcyla
Table 9.66 Drug Profile: Polivy
Table 9.67 Roche: Recent Developments and Future Outlook
Table 11.1 Antibody Drug Conjugates: List of Principal Investigators
Table 13.1 Antibody Drug Conjugates Market: List of Partnerships and Collaborations, 2020-2025
Table 14.1 Antibody-Drug Conjugates Market: List of Funding and Investments, 2020-2025 (till March)
Table 15.1 Patent Analysis: Top CPC Sections
Table 15.2 Patent Analysis: Top CPC Symbols
Table 15.3 Patent Analysis: Top CPC Codes
Table 15.4 Patent Analysis: Summary of Benchmarking Analysis
Table 15.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 15.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 15.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 17.1 List of Conferences Related to Approved Antibody-drug Conjugates
Table 17.2 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 18.1 Promotional / Marketing Strategy: Informative Downloads
Table 18.2 Adcetris: Drug Overview
Table 18.3 Besponsa: Drug Overview
Table 18.4 Enhertu: Drug Overview
Table 18.5 Kadcyla: Drug Overview
Table 18.6 Mylotarg: Drug Overview
Table 18.7 Polivy: Drug Overview
Table 18.8 Trodelvy: Drug Overview
Table 19.1 List of Top Approved Antibody Drug Conjugates
Table 19.2 Adcetris (Pfizer / Takeda Oncology): Information on Success Protocol Analysis Parameters
Table 19.3 Enhertu (Daiichi Sankyo / AstraZeneca): Success Protocol Analysis Parameters
Table 19.4 Kadcyla (Genentech / ImmunoGen): Success Protocol Analysis Parameters
Table 19.5 Padcev (Pfizer / Astellas Pharma): Success Protocol Analysis Parameters
Table 19.6 Polivy (Genentech): Success Protocol Analysis Parameters
Table 19.7 Trodelvy (Gilead Sciences): Success Protocol Analysis Parameters
Table 20.1 Antibody Drug Conjugate Conjugation Technologies: Information on Generation of Technology, Type of Specificity, Type of Conjugation and Drug Antibody Ratio
Table 20.2 Antibody Drug Conjugate Linker and Linker-Payload Technologies: Information on Manufacturer, Type of Linker and Linker Name
Table 21.1 ADCs Non-clinical Studies: Safety Packages Required
Table 21.2 Kadcyla: GLP Toxicology Study Results
Table 21.3 Antibody-drug Conjugates: Dose Limiting Toxicities in Clinical Studies
Table 21.4 Antibody-drug Conjugates: Relationship Between Dose-Limiting Toxicities and Antibody Drug Conjugate Warhead
Table 22.1 Antibody-drug Conjugates Components: Information on the Cost of Different Types of Linkers
Table 22.2 Antibody-drug Conjugates Component: Information on Cost by Type of Cytotoxin
Table 22.3 Price of Marketed Antibody-drug Conjugates
Table 22.4 Price of Marketed Targeted Drugs
Table 23.1 Antibody-drug Conjugates Contract Manufacturing Service Providers: List of Companies
Table 23.2 Antibody-drug Conjugates Contract Manufacturing Service Providers: List of HPAPI and Cytotoxic Payloads Manufacturing Service Providers
Table 23.3 Antibody-drug Conjugates Contract Manufacturing Service Providers: Information on Scale of Operation
Table 23.4 Antibody Drug Conjugate Contract Manufacturing Service Providers: Information on Location of Dedicated Manufacturing Facilities
Table 24.1 Companion Diagnostics: List of Available Tests for Antibody-drug Conjugates
Table 24.2 Companion Diagnostics: Partnerships and Collaborations, 2021-2023
Table 24.3 Companion Diagnostics for Antibody Therapeutics: List of Available / Under Development Tests
Table 26.1 Antibody-Drug Conjugates Market: List of Forecasted Therapies
Table 35.1 Angiex: Key Highlights
Table 35.2 Syndivia: Key Highlights
Table 35.3 BSP Pharmaceuticals: Key Highlights
Table 35.4 PolyTherics: Key Highlights
Table 35.5 CureMeta: Key Highlights
Table 35.6 CytomX: Key Highlights
Table 35.7 NBE-Therapeutics: Key Highlights
Table 35.8 Cerbios-Pharma: Key Highlights
Table 35.9 Eisai: Key Highlights
Table 35.10 AbTis: Key Highlights
Table 35.11 AmbrX: Key Highlights
Table 35.12 Synaffix: Key Highlights
Table 35.13 Pierre Fabre: Key Highlights
Table 35.14 Catalent Pharma Solutions: Key Highlights
Table 35.15 Lonza: Key Highlights
Table 35.16 Piramal Healthcare: Key Highlights
Table 35.17 Ajinomoto Bio-Pharma Services: Key Highlights
Table 35.18 Cardiff University: Key Highlight
Table 36.1 Antibody-Drug Conjugates: Distribution by Stage of Development
Table 36.2 Antibody-Drug Conjugates: Distribution by Target Indication
Table 36.3 Antibody-Drug Conjugates: Distribution by Therapeutics Area
Table 36.4 Antibody-Drug Conjugates: Distribution by Line of Treatment
Table 36.5 Antibody-Drug Conjugates: Distribution by Dosing Frequency
Table 36.6 Antibody-Drug Conjugates: Distribution by Type of Therapy
Table 36.7 Antibody-Drug Conjugates: Distribution by Target Antigen
Table 36.8 Antibody-Drug Conjugates: Distribution by Antibody Isotypes
Table 36.9 Antibody-Drug Conjugates: Distribution by Type of Linker
Table 36.10 Antibody-Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Table 36.11 Antibody-Drug Conjugates: Distribution by Type of Payload
Table 36.12 Antibody-Drug Conjugates Developers: Distribution by Year of Establishment
Table 36.13 Antibody-Drug Conjugates Developers: Distribution by Company Size
Table 36.14 Antibody-Drug Conjugates Developers: Distribution by Location of Headquarters (Region)
Table 36.15 Antibody-Drug Conjugates Developers: Distribution by Location of Headquarters (Country)
Table 36.16 Most Active Players: Distribution by Number of Antibody-Drug Conjugates
Table 36.17 AbbVie: Annual Revenues, FY 2021-FY 2024 (USD Billion)
Table 36.18 ADC Therapeutics: Annual Revenues, FY 2021-9M FY 2024 (USD Million)
Table 36.19 Astellas Pharma: Annual Revenues, FY 2021-9M FY 2024 (YEN Billion)
Table 36.20 AstraZeneca: Annual Revenues, FY 2021-FY 2024 (USD Billion)
Table 36.21 Daiichi Sankyo: Annual Revenues, FY 2021-9M FY 2024 (JPY Billion)
Table 36.22 Gilead Sciences: Annual Revenues, FY 2021-FY 2024 (USD Billion)
Table 36.23 GSK: Annual Revenues, FY 2021-FY 2024 (GBP Billion)
Table 36.24 Kelun-Biotech: Annual Revenues, FY 2022-FY 2024 (RMB Million)
Table 36.25 Merck: Annual Revenues, FY 2021-FY 2024 (USD Billion)
Table 36.26 Pfizer: Annual Revenues, FY 2021-FY 2024 (USD Billion)
Table 36.27 RemeGen: Annual Revenues, FY 2021-FY 2024 (RMB Million)
Table 36.28 Roche: Annual Revenues, FY 2021-FY 2024 (CHF Billion)
Table 36.29 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2021-2024
Table 36.30 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2021-2024
Table 36.31 Clinical Trial Analysis: Distribution by Trial Phase
Table 36.32 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Table 36.33 Clinical Trial Analysis: Distribution by Trial Status
Table 36.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2021–2024
Table 36.35 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Status
Table 36.36 Clinical Trial Analysis: Distribution by Patient Gender
Table 36.37 Clinical Trial Analysis: Distribution by Study Design
Table 36.38 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 36.39 Leading Industry Players: Distribution by Number of Clinical Trials
Table 36.40 Most Active Non-Industry Players: Distribution by Number of Trials
Table 36.41 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 36.42 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Table 36.43 KOL Analysis: Distribution by Role of KOLs
Table 36.44 KOL Analysis: Distribution by Qualification(s)
Table 36.45 KOL Analysis: Distribution by Type of Organization
Table 36.46 KOL Analysis: Distribution by Affiliated Organization
Table 36.47 KOL Analysis: Distribution by Affiliated Organization
Table 36.48 Most Prominent KOLs: Distribution by RA Score
Table 36.49 Most Prominent KOLs: Comparison of RA Score and Third-Party Score
Table 36.50 Antibody-Drug Conjugates Clinical Studies: Distribution by Trial Registration Year and Type of Therapy
Table 36.51 Antibody Drug Conjugate-based Combination Therapies: Distribution by Phase of Development
Table 36.52 Antibody Drug Conjugate-based Combination Therapies: Distribution by Trial Status
Table 36.53 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication
Table 36.54 Most Popular Antibody-Drug Conjugates Used in Combination Therapies: Distribution by Number of Trials
Table 36.55 Most Popular Drug Classes Used in Antibody Drug Conjugate-based Combination Therapies: Distribution by Number of Trials
Table 36.56 Partnerships and Collaborations: Cumulative Year-wise Trend, 2020-2025
Table 36.57 Partnerships and Collaborations: Distribution by Type of Partnership
Table 36.58 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2020-2025
Table 36.59 Partnerships and Collaborations: Distribution by Type of Partner
Table 36.60 Most Active Players: Distribution by Number of Partnerships
Table 36.61 Partnerships and Collaborations: International and Local Agreements
Table 36.62 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 36.63 Funding and Investment Analysis: Cumulative Distribution of Instances, 2020-2025
Table 36.64 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, 2020-2025 (USD Million)
Table 36.65 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 36.66 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 36.67 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding
Table 36.68 Most Active Players: Distribution by Number of Funding Instances
Table 36.69 Most Active Players: Distribution by Amount Invested (USD Million)
Table 36.70 Funding and Investment Analysis: Distribution of Funding Instances by Region
Table 36.71 Patent Analysis: Distribution by Type of Patent
Table 36.72 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2021-2024
Table 36.73 Patent Analysis: Cumulative Distribution by Patent Application Year, Pre 2019 -2024
Table 36.74 Patent Analysis: Cumulative Year-wise Distribution of Patent Applications by Publication Year, 2021-2025
Table 36.75 Patent Analysis: Distribution by Patent Jurisdiction
Table 36.76 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2019-2023
Table 36.77 Leading Industry Players: Distribution by Number of Patents
Table 36.78 Leading Non-Industry Players: Distribution by Number of Patents
Table 36.79 Leading Individual Assignees: Distribution by Number of Patents
Table 36.80 Patent Analysis: Distribution by Patent Age
Table 36.81 Grants Analysis: Cumulative Distribution by Year of Grant, 2020-2025
Table 36.82 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2020-2025
Table 36.83 Grants Analysis: Distribution by Funding Institute Center
Table 36.84 Grants Analysis: Distribution by Support Period
Table 36.85 Grants Analysis: Distribution by Type of Grant Applications
Table 36.86 Grants Analysis: Distribution by Purpose of Grant Award
Table 36.87 Grants Analysis: Distribution by Activity Code
Table 36.88 Grants Analysis: Distribution by Study Section Involved
Table 36.89 Popular NIH Departments: Distribution by Number of Grants
Table 36.90 Prominent Program Officers: Distribution by Number of Grants
Table 36.91 Popular Recipient Organizations: Distribution by Number of Grants
Table 36.92 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Table 36.93 Grants Analysis: Distribution by Region of Recipient Organization
Table 36.94 Antibody-Drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing
Table 36.95 Antibody-Drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing (With Licensing Fees)
Table 36.96 Antibody-Drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing (With Licensing Fees)
Table 36.97 Antibody-Drug Conjugate Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Table 36.98 Companion Diagnostics for Antibody Therapeutics: Distribution by Type of Cancer
Table 36.99 Companion Diagnostics Applicable to Antibody-Drug Conjugates: Distribution by Key Players
Table 36.100 Global Antibody-Drug Conjugates Market: Historical Trends (Since 2023) and Forecasted Estimates, Till 2035, Base Scenario (USD Billion)
Table 36.101 Global Antibody-Drug Conjugates Market: Forecasted Estimates, Till 2035, Conservative Scenario (USD Billion)
Table 36.102 Global Antibody-Drug Conjugates Market: Forecasted Estimates, Till 2035, Optimistic Scenario (USD Billion)
Table 36.103 Antibody-Drug Conjugates Market: Distribution by Target Indication, 2025, 2030 and 2035 (USD Billion)
Table 36.104 Antibody-Drug Conjugates Market for Breast Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.105 Antibody-Drug Conjugates Market for Lung Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.106 Antibody-Drug Conjugates Market for B-cell Lymphoma: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.107 Antibody-Drug Conjugates Market for Multiple Myeloma: Forecasted Estimates, Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.108 Antibody-Drug Conjugates Market for Ovarian Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.109 Antibody-Drug Conjugates Market for Renal Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.110 Antibody-Drug Conjugates Market for Gastric Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.111 Antibody-Drug Conjugates Market for Hodgkin’s Lymphoma: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.112 Antibody-Drug Conjugates Market for Other Target Indications: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.113 Global Antibody-Drug Conjugates Market: Distribution by Therapeutic Area, 2025, 2030 and 2035 (USD Billion)
Table 36.114 Antibody-Drug Conjugates Market for Solid Tumor: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.115 Antibody-Drug Conjugates Market for Hematological Cancer: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.116 Global Antibody-Drug Conjugates Market: Distribution by Linker, 2025, 2030 and 2035 (USD Billion)
Table 36.117 Antibody-Drug Conjugates Market for Tetrapeptide-based Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.118 Antibody-Drug Conjugates Market for Valine-citrulline Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.119 Antibody-Drug Conjugates Market for SMCC Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.120 Antibody-Drug Conjugates Market for Maleimidocaproyl Linker: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.121 Antibody-Drug Conjugates Market for Maleimide Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.122 Antibody-Drug Conjugates Market for Sulfo-SPDB Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.123 Antibody-Drug Conjugates Market for Tetrapeptide-Maleimide-Linker: Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.124 Antibody-Drug Conjugates Market for GGFG (Peptide) Linker: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.125 Antibody-Drug Conjugates Market for Other Linker: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.126 Global Antibody-Drug Conjugates Market: Distribution by Payload, 2025, 2030 and 2035 (USD Billion)
Table 36.127 Antibody-Drug Conjugates Market for Monomethyl Auristatin E (MMAE) Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.128 Antibody-Drug Conjugates Market for Camptothecin Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.129 Antibody-Drug Conjugates Market for Exatecan Payload: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.130 Antibody-Drug Conjugates Market for DM1 Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.131 Antibody-Drug Conjugates Market for Monomethyl Auristatin F (MMAF) Payload: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.132 Antibody-Drug Conjugates Market for SN-38 / Irinotecan Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.133 Antibody-Drug Conjugates Market for DM4 Payload: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.134 Antibody-Drug Conjugates Market for Other Payloads: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.135 Global Antibody-Drug Conjugates Market: Distribution by Target Antigen, 2025, 2030 and 2035 (USD Billion)
Table 36.136 Antibody-Drug Conjugates Market for HER-2 (ERBB2): Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.137 Antibody-Drug Conjugates Market for TROP-2: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.138 Antibody-Drug Conjugates Market for CD79b: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.139 Antibody-Drug Conjugates Market for BCMA (TNFRSF17 / BCM): Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.140 Antibody-Drug Conjugates Market for FOLR1 (Folate Receptor Alpha): Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.141 Antibody-Drug Conjugates Market for c-MET: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.142 Antibody-Drug Conjugates Market for Nectin-4: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.143 Antibody-Drug Conjugates Market for Integrin Beta-6: Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.144 Antibody-Drug Conjugates Market for Other Antigens: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.145 Global Antibody-Drug Conjugates Market: Distribution Key Geographical Regions, 2025, 2030 and 2035 (USD Billion)
Table 36.146 Antibody-Drug Conjugates Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.147 Antibody-Drug Conjugates Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.148 Antibody-Drug Conjugates Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.149 Antibody-Drug Conjugates Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.150 Antibody-Drug Conjugates Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.151 Antibody-Drug Conjugates Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.152 Antibody-Drug Conjugates Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.153 Antibody-Drug Conjugates Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.154 Antibody-Drug Conjugates Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.155 Antibody-Drug Conjugates Market in Asia-Pacific and Rest of the World: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.156 Antibody-Drug Conjugates Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.157 Antibody-Drug Conjugates Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.158 Antibody-Drug Conjugates Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.159 Antibody-Drug Conjugates Market: Enhertu (Trastuzumab Deruxtecan) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.160 Antibody-Drug Conjugates Market: Polivy (Polatuzumab Vedotin) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.161 Antibody-Drug Conjugates Market: Kadcyla (Trastuzumab Emtansine) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.162 Antibody-Drug Conjugates Market: Trodelvy (Sacituzumab Govitecan) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.163 Antibody-Drug Conjugates Market: Elahere (Mirvetuximab Soravtansine) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.164 Antibody-Drug Conjugates Market: Padcev (Enfortumab Vedotin-ejfv) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.165 Antibody-Drug Conjugates Market: Adcetris (Brentuximab Vedotin) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.166 Antibody-Drug Conjugates Market: Aidixi (Disitamab Vedotin) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.167 Antibody-Drug Conjugates Market: Tivdak (Tisotumab Vedotin) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.168 Antibody-Drug Conjugates Market: Besponsa (Inotuzumab Ozogamicin) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.169 Antibody-Drug Conjugates Market: Sacituzumab Tirumotecan (SKB264) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.170 Antibody-Drug Conjugates Market: Zynlonta (Loncastuximab Tesirine) Sales Forecast, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.171 Antibody-Drug Conjugates Market: Datroway (Datopotamab Deruxtecan) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.172 Antibody-Drug Conjugates Market: Blenrep (Belantamab Mafodotin) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.173 Antibody-Drug Conjugates Market: Telisotuzumab Vedotin (Teliso-V / ABBV-399) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.174 Antibody-Drug Conjugates Market: Telisotuzumab Vedotin (Teliso-V / ABBV-399) Sales Forecast, Till 2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.175 Antibody-Drug Conjugates Market: Trastuzumab Rezetecan (SHR-A1811) Sales Forecast, 2028-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.176 Antibody-Drug Conjugates Market: DB-1303 (BNT-323) Sales Forecast, 2030-2035, Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.177 Antibody-Drug Conjugates Market: Telisotuzumab Adizutecan (Temab-A / ABBV-400) Sales Forecast, 2031-2035 (USD Billion)
Table 36.178 Antibody-Drug Conjugates Market: JSKN003 Sales Forecast, Till 2035 (USD Billion)
Table 36.179 Antibody-Drug Conjugates Market: Patritumab Deruxtecan (U3-1402 / MK-1020) Sales Forecast, Till 2035 (USD Billion)
Table 36.180 Antibody-Drug Conjugates Market: Ifinatamab Deruxtecan (MK-2400 / DS-7300) Sales Forecast, 2029-2035 (USD Billion)

List of Companies and Organizations

Please reach out to our team for the details.